Journal
OSTEOPOROSIS INTERNATIONAL
Volume 18, Issue 6, Pages 829-831Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s00198-007-0323-2
Keywords
adverse effects; alendronate; osteoporosis
Categories
Ask authors/readers for more resources
Here we describe a 47-year-old postmenopausal woman who had been taking alendronate 70 mg/week for osteoporosis. After two months of alendronate therapy, she developed hepatotoxicity, and no other etiological factors for this besides the alendronate were apparent. After the alendronate therapy was discontinued, the patient's hepatic enzyme levels slowly returned to normal. Hepatotoxicity due to alendronate therapy is a rare but possible adverse effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available